Fertility Preservation and Ovarian Hyperstimulation Syndrome Management in Cancer Care: A Pathophysiological Perspective on Gonadotropin-Releasing Hormone Agonists and Antagonists

Overview

Journal Pathophysiology

Publisher MDPI

Specialty Pathology

Date 2024 Jun 26

PMID 38921726

Authors

Giuliano Bedoschi

Caroline Ingold

Paula Andrea Navarro

Affiliations

Soon will be listed here.

Abstract

This narrative review delves into the evolving landscape of fertility preservation techniques, with a particular focus on their use in patients undergoing oncology treatment that carries a risk of ovarian insufficiency. Advances in established methods such as cryopreservation of oocytes and embryos are highlighted, and the increasing use of gonadotropin-releasing hormone (GnRH) agonists is discussed. The review also addresses the complexities and controversies associated with these approaches, such as the 'flare-up' effect associated with GnRH agonists and the potential of GnRH antagonists to reduce the risk of ovarian hyperstimulation syndrome. Despite advances in fertility preservation, the report highlights the challenges we face, including the need for personalized treatment protocols and the management of associated risks. It calls for continued research and collaboration between healthcare professionals to refine these techniques and ultimately improve reproductive outcomes for patients facing the prospect of fertility-impairing treatment.

Citing Articles

The era of increasing cancer survivorship: Trends in fertility preservation, medico-legal implications, and ethical challenges.

De Paola L, Napoletano G, Gullo G, Circosta F, Vergallo G, Marinelli S Open Med (Wars). 2025; 20(1):20251144.

PMID: 39958979 PMC: 11826245. DOI: 10.1515/med-2025-1144.

Oncofertility and Fertility Preservation for Women with Gynecological Malignancies: Where Do We Stand Today?.

Di Nisio V, Daponte N, Messini C, Anifandis G, Antonouli S Biomolecules. 2024; 14(8).

PMID: 39199331 PMC: 11353009. DOI: 10.3390/biom14080943.

References

Oktay K, Turan V, Bedoschi G, Pacheco F, Moy F . Fertility Preservation Success Subsequent to Concurrent Aromatase Inhibitor Treatment and Ovarian Stimulation in Women With Breast Cancer. J Clin Oncol. 2015; 33(22):2424-9. PMC: 4507464. DOI: 10.1200/JCO.2014.59.3723. View

Oktay K, Bedoschi G . Appraising the Biological Evidence for and Against the Utility of GnRHa for Preservation of Fertility in Patients With Cancer. J Clin Oncol. 2016; 34(22):2563-5. DOI: 10.1200/JCO.2016.67.1693. View

. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. Fertil Steril. 2019; 112(6):1022-1033. DOI: 10.1016/j.fertnstert.2019.09.013. View

Oktay K, Marin L, Bedoschi G, Pacheco F, Sugishita Y, Kawahara T . Ovarian transplantation with robotic surgery and a neovascularizing human extracellular matrix scaffold: a case series in comparison to meta-analytic data. Fertil Steril. 2021; 117(1):181-192. PMC: 8863399. DOI: 10.1016/j.fertnstert.2021.08.034. View

Bedoschi G, Navarro P, Oktay K . Novel insights into the pathophysiology of chemotherapy-induced damage to the ovary. Panminerva Med. 2018; 61(1):68-75. DOI: 10.23736/S0031-0808.18.03494-8. View

Serour G, Aboulghar M, Mansour R, Sattar M, Amin Y, Aboulghar H . Complications of medically assisted conception in 3,500 cycles. Fertil Steril. 1998; 70(4):638-42. DOI: 10.1016/s0015-0282(98)00250-7. View

Marin L, Bedoschi G, Kawahara T, Oktay K . History, Evolution and Current State of Ovarian Tissue Auto-Transplantation with Cryopreserved Tissue: a Successful Translational Research Journey from 1999 to 2020. Reprod Sci. 2020; 27(4):955-962. PMC: 7148200. DOI: 10.1007/s43032-019-00066-9. View

Bates D, Harper S . Regulation of vascular permeability by vascular endothelial growth factors. Vascul Pharmacol. 2003; 39(4-5):225-37. DOI: 10.1016/s1537-1891(03)00011-9. View

Lainas G, Kolibianakis E, Sfontouris I, Zorzovilis I, Petsas G, Tarlatzi T . Outpatient management of severe early OHSS by administration of GnRH antagonist in the luteal phase: an observational cohort study. Reprod Biol Endocrinol. 2012; 10:69. PMC: 3489837. DOI: 10.1186/1477-7827-10-69. View

10.

Li H, Lee V, Lau E, Yeung W, Ho P, Ng E . Cumulative live-birth rate in women with polycystic ovary syndrome or isolated polycystic ovaries undergoing in-vitro fertilisation treatment. J Assist Reprod Genet. 2013; 31(2):205-11. PMC: 3933606. DOI: 10.1007/s10815-013-0151-6. View

11.

Abdel-Rahman O . Impact of timeliness of adjuvant chemotherapy and radiotherapy on the outcomes of breast cancer; a pooled analysis of three clinical trials. Breast. 2018; 38:175-180. DOI: 10.1016/j.breast.2018.01.010. View

12.

Abramov Y, Elchalal U, Schenker J . Febrile morbidity in severe and critical ovarian hyperstimulation syndrome: a multicentre study. Hum Reprod. 1998; 13(11):3128-31. DOI: 10.1093/humrep/13.11.3128. View

13.

Roness H, Gavish Z, Cohen Y, Meirow D . Ovarian follicle burnout: a universal phenomenon?. Cell Cycle. 2013; 12(20):3245-6. PMC: 3885633. DOI: 10.4161/cc.26358. View

14.

Padula A . GnRH analogues--agonists and antagonists. Anim Reprod Sci. 2005; 88(1-2):115-26. DOI: 10.1016/j.anireprosci.2005.05.005. View

15.

Maggi R, Cariboni A, Montagnani Marelli M, Moretti R, Andre V, Marzagalli M . GnRH and GnRH receptors in the pathophysiology of the human female reproductive system. Hum Reprod Update. 2015; 22(3):358-81. DOI: 10.1093/humupd/dmv059. View

16.

Chai W, He H, Li F, Zhang W, He C . Spontaneous ovarian hyperstimulation syndrome in a nonpregnant female patient: a case report and literature review. J Int Med Res. 2020; 48(9):300060520952647. PMC: 7536485. DOI: 10.1177/0300060520952647. View

17.

Macklon N, Stouffer R, Giudice L, Fauser B . The science behind 25 years of ovarian stimulation for in vitro fertilization. Endocr Rev. 2006; 27(2):170-207. DOI: 10.1210/er.2005-0015. View

18.

Al-Inany H, Youssef M, Ayeleke R, Brown J, Lam W, Broekmans F . Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2016; 4:CD001750. PMC: 8626739. DOI: 10.1002/14651858.CD001750.pub4. View

19.

Mor Y, Schenker J . Ovarian hyperstimulation syndrome and thrombotic events. Am J Reprod Immunol. 2014; 72(6):541-8. DOI: 10.1111/aji.12310. View

20.

Timmons D, Montrief T, Koyfman A, Long B . Ovarian hyperstimulation syndrome: A review for emergency clinicians. Am J Emerg Med. 2019; 37(8):1577-1584. DOI: 10.1016/j.ajem.2019.05.018. View